Clinical Trials Logo

Clinical Trial Summary

Background: - Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive state. However, some people may become quite ill when they are infected with a particular virus, possibly because part of their immune system does not respond properly to fight the virus. - Researchers have discovered some reasons why a person may not be able to clear an infection caused by a virus. Some persons have changes in the genes that involve the immune system that result in the inability to properly control infection with a particular virus. Identifying changes in genes that involve the immune system should help scientists better understand how the immune system works to protect people from infection and may help develop new therapies. Objectives: - To study possible immune defects that may be linked to a particular severe viral infection. - To determine if identified immune defects are genetic in origin. Eligibility: - Individuals of any age who have or have had a diagnosis of a virus infection that physicians consider to be unusually severe, prolonged, or difficult to treat. - Relatives of the participants with a severe viral infection may also participate in the study. We will use their blood and/or skin specimens to try to determine if identified immune defects are hereditary. Design: - Prior to the study, the participant's doctor will give researchers the details of the infection, along with medical records for review. Eligible participants will be invited to the NIH Clinical Center for a full evaluation as an outpatient or inpatient. - At the Clinical Center, participants will be treated with the best available therapy for the particular viral infection, and researchers will monitor how the infection responds to the treatment. - Researchers will take intermittent blood samples and conduct other tests (such as skin biopsies) to evaluate the immune system. - During and after the illness, researchers will conduct follow-up visits to determine the course of infection and response to therapy.


Clinical Trial Description

Viral infections in the normal host are usually self-limited as the innate and acquired immune systems mount successful antiviral responses. However, in some instances, apparently immunocompetent persons manifest infections with viruses that would otherwise be observed only in severely immunocompromised hosts. For example, cases of herpes simplex virus (HSV) encephalitis, esophagitis orgastritis, cytomegalovirus (CMV) colitis, adenovirus hepatitis or pneumonitis, recurrent or persistent skin infections caused by HSV or varicella zoster virus (VZV), severe warts caused by human papillomavirus (HPV), recurrent respiratory papillomatosis caused by HPV, severe influenza or respiratory syncytial virus pneumonia, and progressive multifocal leukoencephalopathy (PML) due to JC polyomavirus have been described in apparently immunocompetent patients. While a variety of case reports have described severe viral infections in immunocompetent hosts, the pathogenesis of the vast majority of these cases is not understood, and therapy can be unsuccessful. In this protocol, we will evaluate patients without known immunocompromise, who have severe, persistent, or treatment-refractory viral infections caused by herpesviruses, adenoviruses, polyoma viruses, papillomaviruses, or other viral infections. We will investigate whether certain host or virologic factors predispose these individuals to severe disease. We will also determine the usefulness of various microbiologic tests (e.g., cultures, serology, molecular assays) for following the course of infection in these patients. The physicians in the Clinical Center will provide optimal therapy for these patients, as part of standard of care. Identification of virologic or host factors that predispose these patients to severe viral infections may have important implications for elucidating the pathogenesis of infection and for the development of novel therapies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01011712
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Maria Ploussiou
Phone (240) 627-3240
Email maria.ploussiou@nih.gov
Status Recruiting
Phase
Start date October 1, 2009

See also
  Status Clinical Trial Phase
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT01105000 - Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity
Recruiting NCT06147388 - Regression of Cervical Precancerous Lesions and Associated Risk Factors
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Recruiting NCT06109870 - Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening N/A
Completed NCT03082950 - HPV Infections, Cancer of the Vulva and Therapeutical Success
Recruiting NCT01512784 - Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults Phase 3
Recruiting NCT05363709 - BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients Phase 2
Completed NCT01231945 - Low-Cost Molecular Cervical Cancer Screening Study N/A
Recruiting NCT05996016 - Gut and Vaginal Microbiota Profile Study for HIV Women
Completed NCT05907187 - Research in Ethno-Medicine and Education (REMED) N/A
Completed NCT05616767 - Prevention and Screening for Early Detection of HPV-related Cancers in Gay and Bisexual Men in Tanzania N/A
Completed NCT02247999 - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Terminated NCT01468636 - A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Phase 4
Active, not recruiting NCT04965792 - Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Active, not recruiting NCT05006833 - Text and Talk: A Multi-level Intervention to Increase Provider HPV Vaccine Recommendation Effectiveness N/A
Enrolling by invitation NCT06120205 - SELF-CERV Pivotal Study: SELF-Collection for CERVical Cancer Screening N/A
Recruiting NCT05208710 - PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers Early Phase 1
Completed NCT05462249 - Impact of Catch-up HPV Vaccination
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4